Article in ACS applied bio materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Edwin J BaldelomarXN Biotechnologies, LLC, St. Louis, Missouri 63110, United States.ORCID 0000-0002-3482-373X
Hanwen ZhangMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri 63110, United States.
Daniel ThorekMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri 63110, United States.ORCID 0000-0003-2437-1239
Jennifer R CharltonDepartment of Pediatrics, Division of Nephrology, University of Virginia, Charlottesville, Virginia 22904, United States.
Patrick D WalkerArkana Laboratories, Little Rock, Arkansas 72211, United States.
Leslie D WilsonDivision of Comparative Medicine, Washington University in St. Louis, St. Louis, Missouri 63110, United States.
Kasey C EmotoDepartment of Biology, University of Hawaii at Manoa, Honolulu, Hawai'i 96822, United States.
Veronica Clavijo JordanAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Charlestown, Massachusetts 02115, United States.ORCID 0000-0002-1468-164X
David E ReichertMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri 63110, United States.ORCID 0000-0003-3432-8998
Kooresh ShoghiMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri 63110, United States.
Kevin M BennettMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri 63110, United States.
Funding
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Single-Cell Epigenomics, Transcriptomics, and Bioinformatics CoreP50DK096373 · NIDDK · UNIVERSITY OF VIRGINIA · PI Silvia Medrano · 2012 to 2026
$13.8M
Washington University Institute of Clinical and Translational Sciences (TL1)TL1TR002344 · NCATS · WASHINGTON UNIVERSITY · PI Jay F. Piccirillo · 2017 to 2026
$8.5M
94 TESLA MR SCANNER FOR MURINE IMAGING: IMAGINGS10RR019911 · NCRR · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI BERR, STUART S · 2005 to 2005
$2.0M
Comprehensive MRI-based evaluation of human renal microstructureR01DK111861 · NIDDK · UNIVERSITY OF VIRGINIA · PI BENNETT, KEVIN M, CHARLTON, JENNIFER R · 2017 to 2020
$1.8M
Cellular and Molecular Mechanisms of Fatty Liver DiseaseR01DK111052 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI YU, LIQING · 2016 to 2019
$1.4M
Noninvasive MRI techniques to detect pathology in murine models of renal diseaseR01DK110622 · NIDDK · WASHINGTON UNIVERSITY · PI BENNETT, KEVIN M, CHARLTON, JENNIFER R · 2017 to 2019
$1.0M
Translational imaging tools to nondestructively measure nephron massR41DK129138 · NIDDK · XN BIOTECHNOLOGIES, LLC · PI BENNETT, KEVIN M · 2021 to 2021
In this work, we develop recombinant human cationic ferritin (rHCF) as a contrast agent to detect glomeruli in the kidney using positron emission tomography (PET). We first expressed recombinant human ferritin (rHF) in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development and Use of Human Recombinant · full record | OpenQuestion